| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Bacterial topoisomerase IV (Topo IV) and DNA gyrase (Topo II/DNA gyrase)
|
|---|---|
| ln Vitro |
Gepotidacin S enantiomer is a gepotidacin S enantionmer.
|
| ln Vivo |
GSK2140944's minimum inhibitory concentrations (MICs) for the six MRSA isolates range from 0.125 to 0.5 mg/L. The range of ELF penetration ratios is 1.1 to 1.4. In neutropenic mice, maximal decreases of 1.1 to 3.1 log10 CFU have been observed. For stasis and 1-log-unit decreases, the mean fAUC/MIC ratios needed are 59.3 ± 34.6 and 148.4 ± 83.3, respectively.
|
| Enzyme Assay |
Bacterial Topo IV decatenation assay: Recombinant MRSA or N. gonorrhoeae Topo IV was purified and resuspended in assay buffer containing ATP and kinetoplast DNA (kDNA, substrate for decatenation). Serial concentrations of Gepotidacin (0.01–1 μM) were pre-incubated with the enzyme for 15 minutes at 37°C. The reaction was initiated by adding kDNA, incubated for 30 minutes at 37°C, and terminated by adding SDS-EDTA buffer. DNA products were separated by 1% agarose gel electrophoresis, stained with ethidium bromide, and visualized under UV light. The decatenation activity was quantified by densitometry, and IC50 was calculated as the concentration inhibiting 50% of Topo IV activity [2][4]
|
| Cell Assay |
MIC determination by broth microdilution: Bacterial strains (e.g., MRSA, N. gonorrhoeae, S. pneumoniae) were cultured to mid-logarithmic phase and adjusted to 5×10⁵ CFU/mL in cation-adjusted Mueller-Hinton broth (CAMHB). Gepotidacin was serially diluted (0.008–64 μg/mL) in 96-well plates, and bacterial suspension was added to each well. Plates were incubated at 35°C for 16–20 hours under aerobic conditions (5% CO₂ for fastidious organisms). The MIC was defined as the lowest drug concentration inhibiting visible bacterial growth [1][2][4]
|
| Animal Protocol |
Mice: GSK2140944 s.c. in single doses of 6.25, 50, or 200 mg/kg is given to groups of 48 infected mice at 3 h postinoculation (0 h) for neutropenic pharmacokinetic studies. Using a cardiac puncture, blood samples are taken from groups of six mice at five minutes and 0.25, 0.5, 1, 1.5, 2, 3, and 4 hours after the dose for doses of 6.25 or 50 mg/kg, and at five minutes and 0.25, 0.5, 1, 1.5, 2, 4, and 6 hours after the dose for 200 mg/kg[4].
|
| References |
|
| Additional Infomation |
Gepotidacin is a first-in-class triazaacenaphthylene antibacterial targeting bacterial DNA gyrase and topoisomerase IV. Its target is similar to that of fluoroquinolone antibacterials - e.g. [ciprofloxacin] - while being structurally and pharmacologically distinct. By inhibiting two distinct bacterial enzymes, a lower potential for the development of resistance to gepotidacin is expected. In March 2025, gepotidacin was approved by the FDA for the treatment of uncomplicated urinary tract infections in select patients. In December later the same year, the FDA approved another indication for gepotidacin for the treatment of uncomplicated urogenital gonorrhea.
Gepotidacin is a Triazaacenaphthylene Bacterial Type II Topoisomerase Inhibitor. The mechanism of action of gepotidacin is as a Topoisomerase 2 Inhibitor, and Topoisomerase 4 Inhibitor, and P-Glycoprotein Inhibitor, and Cytochrome P450 3A4 Inhibitor, and Cholinesterase Inhibitor.
|
| Molecular Formula |
C24H28N6O3
|
|---|---|
| Molecular Weight |
448.517524719238
|
| Exact Mass |
448.222
|
| Elemental Analysis |
C, 64.27; H, 6.29; N, 18.74; O, 10.70
|
| CAS # |
2319789-82-5
|
| Related CAS # |
Gepotidacin;1075236-89-3; 2319789-82-5; 1624306-20-2; 1075235-46-9
|
| PubChem CID |
100214166
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
0.1
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
5
|
| Heavy Atom Count |
33
|
| Complexity |
893
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
O=C1C=NC2C=CC(N3C=2N1[C@H](C3)CN1CCC(CC1)NCC1C=C2C(=CN=1)OCCC2)=O
|
| InChi Key |
PZFAZQUREQIODZ-IBGZPJMESA-N
|
| InChi Code |
InChI=1S/C24H28N6O3/c31-22-4-3-20-24-29(22)15-19(30(24)23(32)13-27-20)14-28-7-5-17(6-8-28)25-11-18-10-16-2-1-9-33-21(16)12-26-18/h3-4,10,12-13,17,19,25H,1-2,5-9,11,14-15H2/t19-/m0/s1
|
| Chemical Name |
(3S)-3-[[4-(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione
|
| Synonyms |
Gepotidacin S enantiomer; Gepotidacin (S enantiomer); 2319789-82-5; (3S)-3-({4-[({2H,3H,4H-pyrano[2,3-c]pyridin-6-yl}methyl)amino]piperidin-1-yl}methyl)-1,4,7-triazatricyclo[6.3.1.0,4,12]dodeca-6,8(12),9-triene-5,11-dione; (3S)-3-[[4-(3,4-dihydro-2H-pyrano[2,3-c]pyridin-6-ylmethylamino)piperidin-1-yl]methyl]-1,4,7-triazatricyclo[6.3.1.04,12]dodeca-6,8(12),9-triene-5,11-dione; ...
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 5 mg/mL (11.15 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.5 mg/mL (1.11 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 0.5 mg/mL (1.11 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 5.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. View More
Solubility in Formulation 3: ≥ 0.5 mg/mL (1.11 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.2296 mL | 11.1478 mL | 22.2955 mL | |
| 5 mM | 0.4459 mL | 2.2296 mL | 4.4591 mL | |
| 10 mM | 0.2230 mL | 1.1148 mL | 2.2296 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
